Pharmacokinetics, Safety, and Tolerability of GLPG0259, a Mitogen-Activated Protein Kinase-Activated Protein Kinase 5 (MAPKAPK5) Inhibitor, Given as Single and Multiple Doses to Healthy Male Subjects

Author： Namour Florence  

Publisher： Adis International

ISSN： 1174-5886

Source： Drugs in R&D, Vol.12, Iss.3, 2012-09, pp. : 141-163

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

5-HT 1A receptor-mediated regulation of mitogen-activated protein kinase phosphorylation in rat brain

By Chen J.   Shen C.   Meller E.  

European Journal of Pharmacology, Vol. 452, Iss. 2, 2002-10 ,pp. : 155-162

Elsevier

Access to resources Recommend Favorite

Novel 8-benzoylimidazo[1,2-a] pyridin-5-one mitogen-activated protein kinase inhibitors

By  

Expert Opinion on Therapeutic Patents, Vol. 13, Iss. 10, 2003-10 ,pp. : 1663-1666

Informa Healthcare

Access to resources Recommend Favorite

Safety, tolerability, and pharmacokinetics of single oral doses of tofacitinib, a Janus kinase inhibitor, in healthy volunteers

By  

Clinical Pharmacology In Drug Development, Vol. 4, Iss. 2, 2015-03 ,pp. : 83-88

John Wiley & Sons Inc

Access to resources Recommend Favorite

3D-QSAR Analysis on Pyrrolopyridine Analogs as Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MK-2) Inhibitors

By  

Letters in Drug Design & Discovery, Vol. 4, Iss. 8, 2007-12 ,pp. : 557-561

Bentham Science Publishers

Access to resources Recommend Favorite

Mitogen-activated protein kinase phosphatase: a negative regulator of the mitogen-activated protein kinase cascade

By Haneda M.   Sugimoto T.   Kikkawa R.  

European Journal of Pharmacology, Vol. 365, Iss. 1, 1999-01 ,pp. : 1-7

Elsevier

Access to resources Recommend Favorite